Objective
Alpha-mannosidosis is a rare, degenerative and chronic disease with multiple factors contributing to the degrees of progression. Since these patients are born healthy and exhibiting a slow progression of clinical symptoms, an effective therapy initiated at early age would contribute to a normal development. Thus, this Project is undertaken to reach such a therapy. Due to the complexity of the disease, this Project requires an international effort with a plethora of different techniques and disciplines involved. The Project will aim to reach a critical mass of understanding on both the molecular and path physiological level, and to use this knowledge to develop new strategies for therapy, using a mouse model of the disease. Based on these studies a protocol for clinical trials in humans will be designed, and a company within the Partnership will initiate a commercial production of a therapeutic agent.
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
9037 TROMSOE
Norway